Hesperidin as a preventive resistance agent in MCF-7 breast cancer cells line resistance to doxorubicin

By NUNUK ARIES NURULITA
**Hesperidin as a preventive resistance agent in MCF-7 breast cancer cells line resistance to doxorubicin**

Rifki Febriansah, Dyaningtias Dewi Pamungkas Putri, Sarmoko, Nunuk Aries Nurulita, Edy Meiyanto, Agung Endro Nugroho

**ABSTRACT**

Objective: To evaluate of hesperidin to overcome resistance of doxorubicin in MCF-7 resistant doxorubicin cells (MCF-7/Dox) in cytotoxicity apoptosis and P-glycoprotein (Pgp) expression in combination with doxorubicin.

Methods: The cytotoxic properties, 50% inhibition concentration (IC50) and its combination with doxorubicin in MCF-7 cell lines resistant to doxorubicin (MCF-7/Dox) cells were determined using MTT assay. Apoptosis induction was examined by double staining assay using ethidium bromide-acridine orange. Immunocytochemistry assay was performed to determine the level and localization of Pgp.

Results: Single treatment of hesperidin showed cytotoxic activity on MCF-7/Dox cells with IC50 value of 11 μmol/L. Thus, combination treatment from hesperidin and doxorubicin showed additive and antagonist effect (CI>1.0). Hesperidin did not increase the apoptotic induction, but decreased the Pgp expressions level when combined with doxorubicin in low concentration.

Conclusions: Hesperidin has cytotoxic effect on MCF-7/Dox cells with IC50 of 11 μmol/L. Hesperidin did not increased the apoptotic induction combined with doxorubicin. Co-chemotherapy application of doxorubicin and hesperidin on MCF-7/Dox cells showed synergism effect through inhibition of Pgp expression.

**KEYWORDS**

Hesperidin, Doxorubicin, MCF-7/Dox cells line, Apoptosis, Pgp expression
1. Introduction

Drug resistance is one of the problems in cancer therapy, especially in breast cancer. Breast cancer is the first ranked cases of cancer in women worldwide. In developing countries, breast cancer is the second leading cause of death after cervical cancer. In Indonesia, breast cancer patients as much as 12.10%, are the second largest number after cervical cancer (19.18%). The high mortality rate indicates the treatment with chemotherapy has not overcome the cancer. Strategies and the development of breast cancer treatment should be pursued. Problems in the chemotherapy of breast cancer becomes larger, since the emergence of breast cancer resistance to chemotherapy agents[1].

Breast cancer cell resistance to chemotherapeutic agents is caused by various factors, but it is predominantly due to increased Akt activity and expression of multi-drug resistance 1 (MDR1) gene, the gene encoding P-glycoprotein (Pgp) after administration of doxorubicin[2,3]. Because of these problems, the development of breast cancer chemotherapy directed to the combination of doxorubicin with other compounds (co-chemotherapy) that can increase the effectiveness of doxorubicin[4]. One of the proteins that regulate the proliferation and survival genes is NF-κB[5]. Hesperidin, a citrus flavonoid showed strong toxic effect in Caco-2, CEM/ADR5000 and CCRF-CEM cancer cell lines with IC50, 195, 230 and 95 μmol/L, respectively[6]. Hesperidin also showed antiproliferative effect in MCF-7 cells transfected with green fluorescent protein (GFP)/alpha-tubulin (MCF-7-GFP-Tubulin)[7]. It is also reported that hesperidin protective effect in Benzo(a)pyrene induced testicular toxicity paradigm and repaired the function of lactate dehydrogenase, superoxide dismutase, and glutathione-S-transferase enzyme[8]. Previous study has reported that hesperidin could induce apoptosis in human colon cancer cells through Caspase-3 (CASP3) activation. Hesperidin down-regulated the protein expression of pro-CASP3, and upregulated the level of active CASP3[9].

This study was conducted to determine the effect of hesperidin performed on MCF-7, MCF-7/Dox cells. Cytotoxicity effect of hesperidin, apoptosis induction and Pgp expression observations made on single and combination with
doxorubicin. The results of this study is expected to be used as a reference for further research in order to explore hesperidin as an alternative to chemotherapy agent in breast cancer therapy.

2. Materials and methods

2.1. Chemical and reagent

Hesperidin, dimethylsulfoxide (DMSO), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium-bromide (MTT) were purchased from Sigma Chemical Co., St Louis, MO, USA; rabbit anti-Pgp and horseradish peroxidase-conjugated goat antimouse or anti-rabbit secondary antibodies, CA; Dulbecco’s modified Eagle medium (DMEM) high glucose medium and fetal bovine serum from Gibco, Grand Island, NY; 96-well plates from Iwaki.

2.2. Cell culture and cytotoxicity assay

MCF-7 and MCF-7/Dox human breast cancer cell line was a generous gift from the laboratory of Prof. M Kawaichi (NAIST, Japan). Cells maintained in DMEM high glucose medium supplemented with 10% fetal bovine serum, 1% penicillin-streptomycin at 37 °C in 5% CO2 incubator. To study the cytotoxic effect of hesperidin, confluent cell cultures were trypsinized and seeded in 96-well plates at a density of $1 \times 10^4$ cells per well in growth medium. After 24 h, cells were treated with various concentrations of hesperidin (dissolved in DMSO as a stock solution). The DMSO concentration in the final cell treatment solutions was less than 0.1%. After 24 h of treatments, cells were washed with Phosphate Buffer Solution (PBS) and 100 μL of MTT solution (0.5 mg/mL in DMEM medium) was added. Four hours later, the precipitated formazan was dissolved in 100 μL of sodium dodecyl sulfonate stopper reagent. Cell viability was determined by measuring the absorbance at 595 nm using microplate reader (Biorad). In this study, the drug concentration required to inhibit cell growth by 50% (IC50) was determined from a plot of percent cell viability from control untreated cells versus treated cells.
2.3. Apoptotic assay

Apoptosis was detected using acridine orange-ethidium bromide staining (acridine orange/ethidium bromide double staining). MCF-7/Dox cells (5 × 10^4 cells/well) were seeded on cover slips in 24-well plates until 50%-60% confluent. Cells were incubated with hesperidin alone, doxorubicin alone and their combination for 24 h. Culture medium was removed and cells were washed with PBS. Coverslips were placed into object-glass and added with 10 μL 1X working solution acridine orange (Sigma)-ethidium bromide (Sigma), observed using fluorescence microscopy (Zeiss MC 80). Apoptotic cells which had lost their membrane integrity appeared orange and showed morphological features of apoptosis. Cells were identified as apoptotic on the basis of specific morphological criteria, including condensation and fragmentation of chromatin, and formation of apoptotic bodies.

2.4. Immunocytochemistry assay

MCF-7 and MCF-7/Dox cells were plated at 5 × 10^4 cells/well and cultured in 24-wells plate at cover slip until 80% confluent. At time 0, medium was replaced by fresh complete medium with hesperidin 3.5 μmol/L and doxorubicin 230 nmol/L and placed in CO2 5% incubator at 37 °C for 18 h. Then, cells were harvested and were washed with PBS and fixed with cold methanol for 10 min at freezer -40 °C. Cells washed and blocked in hydrogen peroxide blocking solution for 10 min at room temperature. After that, cells washed with PBS and incubated with prediluted blocking serum for 10 min at room temperature. Cells were stained for 1 h at room temperature with primary Pgp antibody. After washing three times in PBS, secondary antibody were applied for 15-30 min, 1:2 in PBS and added 5% AB serum then washed with PBS three times. The slide was incubated with streptavidin-biotin complex for 15 min, 1:2 in PBS and added 5% AB serum and washed three times in PBS. Slides were incubated in 3,3 diaminobenzidin solution for 3-8 min and washed with aquadest. Cells were counterstained for 3-4 min with Mayer-Haematoksisilin. After incubation, cover slip washed with aquadest and then immersed with xylol and alcohol. Protein expression was assessed under light microscope. Positive expression will give a
dark brown colour in cell membrane and cells with no expression will give purple colour.

3. Results

3.1. Effect of hesperidin and its combination with doxorubicin on cell viability

Cell viability assay was done to determine the IC50 of hesperidin alone and its combination with doxorubicin on MCF-7/Dox cells. All of these compounds showed growth inhibitory effect in dose dependent manner. Hesperidin and doxorubicin had the IC50 values of 11 μmol/L (Figure 1) and 700 nmol/L, respectively. The combination of hesperidin and doxorubicin increased the viability cells higher than hesperidin alone (Figure 2). This result showed that the combination resulted antagonist effect.

3.2. Effect of hesperidin and doxorubicin on apoptosis induction

All of hesperidin or doxorubicin alone were capable of inducing apoptosis at inhibitory concentration, but when they were combined does not showed apoptotic induction (Figure 3). The green fluorescence indicates the viable cells while the orange-red fluorescence indicates the death cells. Apoptotic cells show the occurrence of chromatin condensation and the orange-red apoptotic bodies. Combination of hesperidin and doxorubicin appeared does not showed apoptotic induction.

3.3. Effect of hesperidin and doxorubicin toward Pgp expression on MCF-7/Dox cells line

To confirm the mechanism of hesperidin and its combination with doxorubicin induced apoptosis, this research observed the effect of hesperidin, doxorubicin and their combination on Pgp expression using immunocytochemistry method. Interestingly, the expression of Pgp on the hesperidin and doxorubicin -treated cells was decreased compare to the control cells. The decreasing level of Pgp expression on the combination treated cells was higher than on the hesperidin or doxorubicin single treated cells (Figure 4). Moreover, the increasing level of Pgp
expression on the both single compared with combination treated cells showed significantly different, but still higher than the control cells. These data showed that the combination more potent to reduce the Pgp expression on the MCF-7/Dox cells than single treatment.

Tests were carried out by incubating $5 \times 10^3$ MCF-7/Dox cells in 96-well plates for 24 h to adapt, then treated hesperidin concentrations of 1-100 μmol/L, then incubated again for 24 h. Profiles of cell viability expressed mean±SD of 3 experiments (A). Obvious morphological changes and cell populations in the treatment of hesperidin concentrations of 10 (C), 50 (D), and 100 μmol/L (E) compared with controls (B). Black arrow indicates a normal living cells, whereas white arrows indicate the cell morphology changes. Cell morphology observations conducted with an inverted microscope with a magnification of 100 Ⅹ. IC50 of 11 μmol/L obtained from the linear regression calculation of cell viability vs log concentrations with $P<0.05$.

Tests were carried out by incubating $5 \times 10^3$ MCF-7/Dox cells in 96-well plates for 24 h to adapt, then given a single treatment and combination of hesperidin 0.5, 1.25, 2.5 and 3.5 μmol/L, and doxorubicin 35, 87.5, 175 and 233 nmol/L, and then incubated again for 24 h. Profiles of cell viability expressed mean±SD of 3 experiments. Hesperidin is not able to enhance doxorubicin effects in reducing cell viability (A). Changes in cell morphology seen in the treatment of hesperidin least 3.5 μmol/L (C), treatment of 233 nmol/L doxorubicin (D), and the treatment of hesperidin combination of 3.5 μmol/L and 233 μmol/L doxorubicin (E) compared with controls (B). Black arrow indicates a normal living cells, whereas white arrows indicate the cell morphology changes. Cell morphology observations conducted with an inverted microscope with a magnification of 100 Ⅹ. Doxorubicin combination treatment of cell viability 3.5 μmol/L and 233 nmol/L hesperidin did not differ significantly to 233 nmol/L doxorubicin single ($P<0.05$).
A: all cells seen alive in the control; B: incidence of apoptosis treated with 230 nmol/L doxorubicin; C: incidence of apoptosis treated with 3.5 μmol/L hesperidin;

D: Incidence of apoptosis treated with combination of 3.5 μmol/L hesperidin and 230 nmol/L doxorubicin not increased significantly; Arrows: the place where the incidence of apoptotic cells seen any fragmentation of the cell nucleus. Observations made under a fluorescent microscope with a magnification of 100×. Tests were carried out by incubating 5×10^4 MCF-7/Dox cells on coverslips in 24 wells plates for 24 h to adapt, then were subjected to 230 nmol/L doxorubicin, hesperidin 3.5 μmol/L and a combination of both. Ties incubated for 18 h and Pgp staining done as mentioned in the research procedure. Control cells without primary anti-Pgp antibody did not showed the brown color on the cell membrane (A). Control cells with antibodies showed expression of Pgp viewed from the cell membrane of brown color (B). In the doxorubicin group showed expression of the increasingly intense brown color on the cell membrane (C). Hesperidin and combination with doxorubicin (D and E) showed a decrease in the intensity of brown color when compared with doxorubicin single treatment group.

4. Discussion

The aim of this research was to investigate the biological activity of hesperidin to overcome cancer cell resistance because of doxorubicin chemotherapy drugs. MTT assay showed that hesperidin able to increase of MCF-7/Dox cells sensitivity to doxorubicin with IC50 value of 11 μmol/L. It was lower than the MCF-7 (ori) of 200 μmol/L.[10]. The combination of hesperidin with doxorubicin was interesting in overcoming resistance through its action in suppressing the Pgp expression. One of the mechanisms of cancer cell resistance to anticancer agents associated with MDR1 gene expression and the over-expression of Pgp protein, which could pumps the drugs out of cells. The MCF-7/Dox cells resistant to doxorubicin is experiencing over-expression of Pgp. Pgp encoded by the MDR1 gene and protein products transported through endosom with early transport to the plasma membrane. The MCF-7/Dox that overexpression of Pgp has been
successfully made in this study with the method of induction by low concentration of doxorubicin.

**Hesperidin was able to increase the sensitivity of cells**

value to MCF-7/Dox of 11 μmol/ L compared to MCF-7 cells. These results were consistent with several studies which showed that polyphenols such as flavonols quercetin increase the sensitivity of cells that are resistant to daunorubicin[11]. Several other flavonoids like silymarin were able to reverse the function of Pgp[12]. Flavonoid compounds also able to modulate Pgp expression so that the amount of intracellular doxorubicin increase and provide a greater cytotoxic effect.

Doxorubicin is a chemotherapy agent that is widely used in the treatment of various epithelial cancers. In the previous study showed that doxorubicin has a high potential as anticancer agents, Fitriasari et al. (2010) in MCF-7 cells and Junedi et al. (2010) in T47D cells showed that doxorubicin could inhibit cell growth with IC50 values were 460 nmol/L and 15 nmol/L, respectively[13-14].

Mechanism of doxorubicin is formed intercalation with DNA. It will directly affect the transcription and replication. Doxorubicin is able to form a tripartite complex with topoisomerase II and DNA. From the research, it resulted that doxorubicin has IC50 value of 700 nmol/L in MCF-7/Dox cells. On the combination of hesperidin with doxorubicin, it did not show a strong cytotoxic effect and combination index had high value (additive to antagonist effect). This is probably due to flavonoids such as hesperidin which are antioxidants will inhibit the cytotoxic activity of doxorubicin. Research about hesperidin as an antioxidant has been widely reported previously[15]. Mechanism of hesperidin as antioxidant was to inhibit the peroxidation of linoleic acid induced by Fe2+ and autooxidation in membranes cerebral and inhibits the production of reactive oxygen species including hydroxyl radicals and nitric oxide (NO)[16]. In contrast with the anticancer activity of doxorubicin, one of the mechanisms of doxorubicin in inhibiting the progression of cancer is to stimulate the production of reactive oxygen species and NO that would undermine the stability of DNA and eventually will cause death of cancer cells. The combination of
hesperidin with doxorubicin in this study proved to be potent and synergistic in inhibiting cancer cell growth. This is probably due to a mechanism that is opposite from the second agent. This is an interesting research findings, in which a natural compound in combination with chemotherapeutic agents did not always produce a synergistic effect. To explore the mechanism of action of this combination, it is necessary to observe the mechanism of cell death and see that the modulation of protein expression plays a role against the resistance of cancer cells, namely Pgp. The results of apoptosis by double staining method in the treatment of hesperidin (3.5 μmol/L) showed that only a few occurrence of the phenomenon of apoptosis. Similar results are also shown in the treatment of hesperidin combination with doxorubicin, while a single doxorubicin could increase the occurrence of apoptosis. This is consistent with the results of combination between hesperidin and doxorubicin at low concentrations showed no cytotoxic effects, even to additive and antagonistic. This is in line with research of Sakata et al. (2003) which showed that hesperidin can reduce the occurrence of cell apoptosis through its ability to reduce the overproduction of NO as a result of an inhibitory effect on the expression and activity of inducible nitric oxide synthase[17,18]. From the results of Pgp observation was known that the combination of hesperidin with doxorubicin to inhibit the expression of Pgp in MCF-7 /Dox cells. This was shown by a decrease in the intensity of brown color on the cell membrane compared to doxorubicin single treatment. This is consistent with previous studies that flavonoids including hesperidin can be located as a substrate of Pgp on adenosine triphosphate binding site, so that the expression of Pgp will be decreased[19-23]. So the prospect of hesperidin has developed further as Pgp expression-suppressing agents.

Conflict of interest statement

We declare that we have no conflict of interest.

Acknowledgements
We gratefully thanks to DP2M DIKTI (Directorate of higher Education) Ministry of Education Indonesia through HKI research grant 2011 for financial support of this study.

Comments

Background

Drug resistance is one of the problems in cancer therapy, especially in breast cancer. Strategies and the development of breast cancer treatment should be pursued. Problems in the chemotherapy of breast cancer become larger, since the emergence of breast cancer resistance to chemotherapy agents.

Research frontiers

Hesperidin has antiproliferative effect on MCF-7 cells. This study aimed to determine the effect of hesperidin on MCF-7 and MCF-7/Dox cells. The study demonstrated cytotoxicity of hesperidin, apoptosis induction and Pgp expression, when given singly and combination with doxorubicin. The results will be basic research in order to explore hesperidin as an alternative to co-chemotherapy agent in breast cancer therapy.

Related reports

Hesperidin showed strong toxic effect in Caco-2, CEM/ADR5000 and CCRF-CEM cancer cell lines with dangan IC50, 195, 230 and 95 μmol/L, respectively. Hesperidin protects benzo(a)pirene-induced testicular toxicity by repairing the function of lactate dehydrogenase, superoxide dismutase, dan glutathione-S-transferase enzymes. Also, hesperidin is able to induce apoptosis in human colon cancer cell lines by CASP3 activation.

Innovations and breakthroughs

Hesperidin possesses a variety of biological properties, including cancer chemoprevention. In this in vitro study, the authors demonstrated that hesperidin could be used for lowering breast cancer resistance to chemotherapy agents.
Applications

It is well-known that resistance to chemotherapy is one of the major problems to treat breast cancer. This study suggests that hesperidin can be used for reducing resistance to breast cancer chemotherapy, by single treatment or in combination with anti-cancer agents.

Peer review

This is an interesting and valuable research work. The authors demonstrated that hesperidin has cytotoxic effect on MCF-7/Dox cells with IC50 of 11 μmol/L. Hesperidin did not increased the apoptotic induction combined with doxorubicin. Co-chemotherapy application of doxorubicin and hesperidin on MCF-7/Dox cells showed synergism effect.
**Hesperidin as a preventive resistance agent in MCF-7 breast cancer cells line resistance to doxorubicin**

**ORIGINALITY REPORT**

| 30% |
| SIMILARITY INDEX |

**PRIMARY SOURCES**

1. [doaj.org](http://doaj.org)  
   Internet  
   252 words — 8%

2. Zengshuan Ma. "Resveratrol analog trans 3,4,5,4'-tetramethoxystilbene (DMU-212) mediates anti-tumor effects via mechanism different from that of resveratrol", Cancer Chemotherapy and Pharmacology, 12/2008  
   Crossref

3. Sabirin Matsjeh, Respati Tri Swasono, Chairil Anwar, Eti Nurwening Solikhah, Endang Lestari. "Synthesis of 2',4-dihydroxy-3-methoxychalcone and 2',4',4-trihydroxy-3-methoxychalcone as a candidate anticancer against cervical (WiDr), colon (HeLa), and breast (T47d) cancer cell lines in vitro", AIP Publishing, 2017  
   Crossref

   Internet  
   77 words — 2%

5. [ccrc.farmasi.ugm.ac.id](http://ccrc.farmasi.ugm.ac.id)  
   Internet  
   70 words — 2%

   Crossref

activation in human colon cancer cells, SNU-C4", Phytomedicine, 20080125

Zhong, Yan, Fengyi Zhang, Zhongying Sun, Wei Zhou, Zhi-Yu Li, Qi-Dong You, Qing-Long Guo, and Rong Hu. "Drug resistance associates with activation of Nrf2 in MCF-7/DOX cells, and wogonin reverses it by down-regulating Nrf2-mediated cellular defense response", Molecular Carcinogenesis, 2012.

Yuan Yuan, Yu Feng Yao, Sai Nan Hu, Jin Gao, Li-Li Zhang. "MiR-133a Is Functionally Involved in Doxorubicin-Resistance in Breast Cancer Cells MCF-7 via Its Regulation of the Expression of Uncoupling Protein 2", PLOS ONE, 2015

E. Cheong. "Synthetic and naturally occurring COX-2 inhibitors suppress proliferation in a human oesophageal adenocarcinoma cell line (OE33) by inducing apoptosis and cell cycle arrest", Carcinogenesis, 06/03/2004

Fa Yun Zhang. "Naringenin Enhances the Anti-Tumor Effect of Doxorubicin Through Selectively Inhibiting the Activity of Multidrug Resistance-Associated Proteins but not P-glycoprotein", Pharmaceutical Research, 04/2009

www.e-sciencecentral.org

www.tums.ac.ir

www.jbc.org


Edy Meiyanto. "The improvement of doxorubicin activity on breast cancer cell lines by tangeretin through cell cycle modulation", Oriental Pharmacy and Experimental Medicine, 07/05/2011

<table>
<thead>
<tr>
<th>#</th>
<th>Author(s)</th>
<th>Title</th>
<th>Journal</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>24</td>
<td>Ju-Hee Kang</td>
<td>&quot;Involvement of Cox-2 in the metastatic potential of chemotherapy-resistant breast cancer cells&quot;, BMC Cancer, 2011</td>
<td>Crossref</td>
<td></td>
</tr>
<tr>
<td>25</td>
<td></td>
<td></td>
<td>pubs.acs.org</td>
<td></td>
</tr>
<tr>
<td>26</td>
<td></td>
<td></td>
<td>edoc.ub.uni-muenchen.de</td>
<td></td>
</tr>
<tr>
<td>28</td>
<td>Krzysztof Jamroziak</td>
<td>&quot;Pharmacogenomics of MDR1 / ABCB1 Gene: the Influence on Risk and Clinical Outcome of Haematological Malignancies&quot;, Hematology, 4/1/2004</td>
<td>Crossref</td>
<td></td>
</tr>
</tbody>
</table>